Search Medical Condition
Please enter condition
Please choose location

Brandon, Canada Clinical Trials

A listing of Brandon, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (12) clinical trials

Mesalamine 4 g Sachet for the Induction of Remission in Active Mild to Moderate Ulcerative Colitis (UC)

The purpose of this trial is to investigate the safety and efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC. Subject will receive 4 g extended release granules (sachet) once daily.

Phase

0.0 miles

Learn More »

Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active Moderate to Severe Crohn's Disease

This is a four-part Phase 2b study comprised of a 16-week, double-blind, placebo-controlled, Induction Period, a 12-week double-blind, placebo-controlled, Maintenance Period, a 24-week, Open-label Period and a post-treatment 28 week observational safety follow-up period designed to evaluate the short-term efficacy and the short- and long term safety of MEDI2070 in ...

Phase

0.0 miles

Learn More »

Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness

This study assesses Humira's® real-life effectiveness in the management of dermatological manifestations of moderate to severe Hidradenitis Suppurativa (HS).

Phase N/A

0.09 miles

Learn More »

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

The trial is composed of 2 periods: Induction and Maintenance. Patients will be entered into the trial in 2 separate cohorts through the Induction Period (10 weeks) and those patients in clinical response at the end of the Induction Period will proceed through to the Maintenance Period. Participation in these ...

Phase

0.35 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

0.35 miles

Learn More »

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

The purpose of study is to test the effects of an experimental medication GED-0301 (mongersen) in patients who have active Crohn's disease. The study will test GED-0301 compared to placebo for 52 weeks. The study treatment is blinded which means that patients and the study doctor will not know which ...

Phase

0.35 miles

Learn More »

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

This is a long-term active treatment study in patients with Crohn's disease (CD). Subjects who met the early escape criteria in Study GED-0301-CD-002, or subjects who completed Study GED-0301-002 or GED-0301-003, may be eligible for this study. Primary objective is to assess long-term safety of GED 0301. Additional efficacy and ...

Phase

0.35 miles

Learn More »

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase

0.35 miles

Learn More »

A phase 3 research study of an oral investigational medication as induction and maintenance therapy for adults ages 18 to 75 with moderate to severe ulcerative colitis. Note, study participants may receive the investigational medication or placebo. For more information, please visit our study website at: www.TrueNorthStudy.com

Phase

0.35 miles

Learn More »

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is ...

Phase

0.87 miles

Learn More »